Open Access

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature

  • Authors:
    • Feng Chen
    • Qian Zhang
    • Yanjin Wang
    • Siwen Wang
    • Shawein Feng
    • Liyuan Qi
    • Xuefen Li
    • Chong Ding
  • View Affiliations

  • Published online on: April 24, 2018     https://doi.org/10.3892/ol.2018.8558
  • Pages: 9786-9792
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Oral mucosal melanoma (OMM) is an aggressive malignant tumor derived from melanocytes in the oral cavity. The genetic etiology of OMM has not been extensively investigated to date. In the present study, the aim was to detect novel gene mutations in patients with OMM. Mutation analysis of KIT, BRAF and NRAS was conducted by polymerase chain reaction. In addition, the relevant literature was searched using the PubMed database, and previous findings were compared with the results of the present study. Among the 9 patients with OMM examined, KIT, BRAF and NRAS mutations were detected, and these mutations were all observed at a frequency of 11.1% (1/9 patients). Notably, a novel FMNL2 mutation in 2 patients with OMM was identified by exome sequencing. In conclusion, the current study observed KIT, BRAF, NRAS and FMNL2 mutations in patients with OMM, which may be of benefit for elucidating the underlying mechanism of OMM pathogenesis.

References

1 

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J ClinOncol. 27:6199–6206. 2009. View Article : Google Scholar

2 

Nikolaou V and Stratigos AJ: Emerging trends in the epidemiology of melanoma. Br J Dermatol. 170:11–19. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Mihajlovic M, Vlajkovic S, Jovanovic P and Stefanovic V: Primary mucosal melanomas: A comprehensive review. Int J Clin Exp Pathol. 5:739–753. 2012.PubMed/NCBI

5 

Soma PF, Pettinato A, Agnone AM, Donia C, Improta G and Fraggetta F: Oral malignant melanoma: A report of two cases with BRAF molecular analysis. Oncol Lett. 8:1283–1286. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Buery RR, Siar CH, Katase N, Gunduz M, Lefeuvre M, Fujii M, Inoue M, Setsu K and Nagatsuka H: NRAS and BRAF mutation frequency in primary oral mucosal melanoma. Oncol Rep. 26:783–787. 2011.PubMed/NCBI

7 

Meleti M, Leemans CR, Mooi WJ, Vescovi P and van der Waal I: Oral malignant melanoma: A review of the literature. Oral Oncol. 43:116–121. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Rapini RP, Golitz LE, Greer RO Jr, Krekorian EA and Poulson T: Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer. 55:1543–1551. 1985. View Article : Google Scholar : PubMed/NCBI

9 

Gu GM, Epstein JB and Morton TH Jr: Intraoral melanoma: Long-term follow-up and implication for dental clinicians. A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 96:404–413. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Eggermont AM and Robert C: Melanoma: Smart therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol. 11:181–182. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Sabbatino F, Wang Y, Wang X, Ferrone S and Ferrone CR: Emerging BRAF inhibitors for melanoma. Expert Opin Emerg Drugs. 18:431–443. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Romano E, Schwartz GK, Chapman PB, Wolchock JD and Carvajal RD: Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 12:913–922. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI

14 

Colombino M, Lissia A, Franco R, Botti G, Ascierto PA, Manca A, Sini MC, Pisano M, Paliogiannis P, Tanda F, et al: Unexpected distribution of cKIT and BRAF mutations among southern italian patients with sinonasal melanoma. Dermatology. 226:279–284. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, Yuen ST and Leung SY: Cancer Genome Project: BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 58:640–644. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D and Westra WH: Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. 10:3444–3447. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, et al: Absence of BRAF mutations in UV protected mucosal melanomas. J Med Genet. 41:270–272. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Uhara H, Ashida A, Koga H, Ogawa E, Uchiyama A, Uchiyama R, Hayashi K, Kiniwa Y and Okuyama R: NRAS mutations in primary and metastatic melanomas of Japanese patients. Int J Clin Oncol. 19:544–548. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Thompson L: World health organization classification of tumours: Pathology and genetics of head and neck tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI

20 

Curtin JA, Busam K, Pinkel D and Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 24:4340–4346. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q and Grimm EA: Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 17:229–235. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Qu J, Yu F, Hong Y, Guo Y, Sun L, Li X, Zhang J, Zhang H, Shi R, Chen F and Li T: Underestimated PTCH1 mutation rate in sporadic keratocysticodontogenic tumors. Oral Oncol. 51:40–45. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Adzhubei I, Jordan DM and Sunyaev SR: Predicting functional effect of human missense mutations using polyphen-2. Curr Protoc Hum Genet: Chapter 7. Unit7.20. 2013.

24 

Wang K, Li M and Hakonarson H: ANNOVAR: Functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI

25 

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L and Guo J: Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 48:94–100. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI

27 

Cohen Y, Goldenberg-Cohen N, Akrish S, Shani T, Amariglio N, Dratviman-Storobinsky O, Kaplan I, Barshack I and Hirshberg A: BRAF and GNAQ mutations in melanocytic tumors of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 114:778–784. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH, Tsujigiwa H, Tamamura R, Han KN and Nagai N: C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 452:27–32. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP and Besmer P: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 10:3282–3290. 2004. View Article : Google Scholar : PubMed/NCBI

30 

Peyssonnaux C and Eychène A: The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell. 93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI

31 

Platz A, Egyhazi S, Ringborg U and Hansson J: Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 1:395–405. 2008. View Article : Google Scholar : PubMed/NCBI

32 

Malumbres M and Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI

33 

Alexeev V and Yoon K: Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 126:1102–1110. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Lennartsson J, Jelacic T, Linnekin D and Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 23:16–43. 2005. View Article : Google Scholar : PubMed/NCBI

35 

Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J and Ragnarsson-Olding BK: KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res. 17:3933–3942. 2011. View Article : Google Scholar : PubMed/NCBI

36 

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F III, Azar S, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 14:6821–6828. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Schoenewolf NL, Bull C, Belloni B, Holzmann D, Tonolla S, Lang R, Mihic-Probst D, Andres C and Dummer R: Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer. 48:1842–1852. 2012. View Article : Google Scholar : PubMed/NCBI

38 

Gardberg M, Talvinen K, Kaipio K, Iljin K, Kampf C, Uhlen M and Carpén O: Characterization of diaphanous-related formin FMNL2 in human tissues. BMC Cell Biol. 11:552010. View Article : Google Scholar : PubMed/NCBI

39 

Zhu XL, Zeng YF, Guan J, Li YF, Deng YJ, Bian XW, Ding YQ and Liang L: FMNL2 is a positive regulator of cell motility and metastasis in colorectal carcinoma. J Pathol. 224:377–388. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, F., Zhang, Q., Wang, Y., Wang, S., Feng, S., Qi, L. ... Ding, C. (2018). KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. Oncology Letters, 15, 9786-9792. https://doi.org/10.3892/ol.2018.8558
MLA
Chen, F., Zhang, Q., Wang, Y., Wang, S., Feng, S., Qi, L., Li, X., Ding, C."KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature". Oncology Letters 15.6 (2018): 9786-9792.
Chicago
Chen, F., Zhang, Q., Wang, Y., Wang, S., Feng, S., Qi, L., Li, X., Ding, C."KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature". Oncology Letters 15, no. 6 (2018): 9786-9792. https://doi.org/10.3892/ol.2018.8558